GlobeNewswire Inc.T3·8mo ago
CRVO CervoMed Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CRVO
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 15
- List Date
- 1996-06-18
- CIK
- 0001053691
- Next Earnings
- 2026-11-06
- EPS Forecast
- ($0.61) (3 est.)
- Headquarters
- Boston, MA
- Homepage
- https://www.cervomed.com
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | 4.25% | 1.35% | -33.89% | -9.43% |
| Feb | -- | 68.47% | -1.32% | -18.07% | 16.36% |
| Mar | -- | 80.34% | 327.57% | 1.29% | 136.40% |
| Apr | -- | 7.00% | -9.22% | -7.75% | -3.32% |
| May | -- | -21.64% | -31.63% | -16.17% | -23.15% |
| Jun | -- | -12.92% | -22.98% | 3.33% | -10.86% |
| Jul | -- | -19.35% | 39.12% | -29.22% | -3.15% |
| Aug | -22.00% | 50.65% | 8.95% | 1.15% | 9.69% |
| Sep | -20.21% | -9.99% | -19.86% | 15.56% | -8.62% |
| Oct | 78.97% | -5.08% | -12.20% | -45.39% | 4.07% |
| Nov | 9.62% | -15.69% | 41.60% | -4.88%* | 7.66% |
| Dec | -23.70% | -77.69% | -14.32% | -- | -38.57% |
| Total | -6.84% | -54.85% | 164.50% | -81.16% | 5.41% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.22
SMA 50: $2.49
SMA 200: $3.43
Current: $1.56
EMA 12: $1.93
EMA 26: $2.21
MACD: -0.2816 | Signal: -0.0815
BEARISH
ADX (14): 33.26
TREND
+DI: 9.80
−DI: 35.40
Momentum Oscillators
RSI (14): 25.01
OVERSOLD
Stoch %K: 7.77
Stoch %D: 5.94
Williams %R: -89.47
Volume & Volatility
BB Upper: $3.12
BB Lower: $1.31
NEUTRAL
OBV: 419,502,550
Vol SMA 20: 336,602
Vol ROC: 440.86%
ATR: $0.20
True Range: $0.22
HV 20: 126.3%
HV 30: 117.7%
HV 60: 89.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-06T00:00:00 – 2026-11-04T00:00:00
AI Analysis
LLM Stock Analysis Report: CRVO
Executive Summary
BULLISH (Confidence Level: 7)
Key drivers:
- Strong positive news sentiment surrounding neflamapimod's potential treatment options for Amyotrophic Lateral Sclerosis (ALS) and Dementia with Lewy Bodies (DLB)
- Technical indicators suggest a trending market, with the stock price above its SMA 20 and SMA 50
Primary risks:
- High volatility, reflected in beta value of 1.5
- Lack of earnings data, making it difficult to assess fundamental performance
Investment thesis: CRVO is poised for further growth as investors become increasingly aware of neflamapimod's potential therapeutic applications. While high volatility poses a risk, the stock's trending market and strong positive news sentiment provide a solid foundation for future gains.
Recent news sentiment impact: The recent string of positive news headlines has contributed to CRVO's upward momentum, with the stock price responding favorably to each announcement.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Neutral, Long-term (3-12 months): Bullish
Support/Resistance Levels:
- SMA 20: $3.03
- SMA 50: $3.48
- Upper Bollinger Band: $3.98
Momentum Signals:
- RSI interpretation: Neutral (58.12)
- MACD signal: Bearish (-0.05 / Signal: 0.14 / Histogram: -0.19)
- Bollinger Bands position: Squeeze
Volume Analysis: Volume SMA 20: 10886165.22, On-Balance Volume (OBV): 324172006.96, Volume Rate of Change: 12032.11%
News & Sentiment Analysis
Recent Headlines Summary: CRVO has received a series of positive news headlines highlighting neflamapimod's potential therapeutic applications for ALS and DLB.
Sentiment Assessment: Positive (80%)
Catalyst Identification: Upcoming presentations at conferences, such as the 18th CTAD Conference, may further solidify CRVO's growth prospects.
Market Narrative: The positive news sentiment surrounding CRVO has contributed to its upward momentum, with the stock price responding favorably to each announcement.
Risk & Volatility Assessment
Beta Interpretation: High risk (beta: 1.50)
Volatility Regime: Current vs historical volatility levels: Higher than average
Options Market Signals: IV rank: N/A (positive = implied richer than realized), put/call ratios: N/A, unusual activity: None reported
Downside Protection: Support levels: SMA 20 and SMA 50, Risk management considerations: Stop-loss at $2.07 or lower.
Market Context & Positioning
Sector Performance: CRVO's performance is inline with the biotech sector's growth trend.
Institutional Activity: Institutional interest is reflected in the high volume and trading activity.
Correlation Analysis: CRVO has a moderate correlation (0.17) with the overall market, suggesting it may move independently of broader market trends.
Relative Valuation: CRVO is positioned within its trading range, with the recent upward momentum pushing the stock higher.
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $3.03 (support)
- Upper Bollinger Band: $3.98 (resistance)
Breakout/Breakdown Levels: None reported
Time-Sensitive Catalysts: Upcoming presentations at conferences, such as the 18th CTAD Conference.
Risk Management: Stop-loss at $2.07 or lower, position sizing considerations based on recent trading activity.
Please note that this analysis is based solely on publicly available data and should not be considered personalized investment advice.
Generated
News
All CRVO news →
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·12mo ago
GlobeNewswire Inc.T3·12mo ago
GlobeNewswire Inc.T3·13mo ago
GlobeNewswire Inc.T3·14mo ago
GlobeNewswire Inc.T3·15mo ago
GlobeNewswire Inc.T3·21mo ago
Showing 1–10 of 18
Page 1 of 2
CRVO Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.9186
Alpha: -118.27%
Correlation: 0.2095
R-Squared: 4.4%
Stock Volatility: 117.6%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CRVO
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Rockefeller Capital Management Family office Rockefeller family | $0K | #4698 of 4729 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CRVO Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
CRVO Insider Trading (Form 4)
Latest: 2026-10-23Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-23 | Kelly Blackburn | EVP, Clinical Development | Grant (A) | +19,100 opt | — | EDGAR | |
| 2026-10-23 | Matthew Winton | Chief Commercial and Business | Grant (A) | +19,100 opt | — | EDGAR | |
| 2026-10-23 | Mark De Rosch | EVP, RA and GA and PgM | Grant (A) | +19,100 opt | — | EDGAR | |
| 2026-06-15 | Joshua S Boger | Director | Buy (P) | +955,414 | $3.14 | $3.00M | EDGAR |
| 2026-06-10 | Jeffrey V. Poulton | Director | Grant (A) | +8,150 opt | — | EDGAR | |
| 2026-06-10 | Sylvie Gregoire | Director | Grant (A) | +8,150 opt | — | EDGAR | |
| 2026-06-10 | John J Alam | CEO & President | Grant (A) | +8,150 opt | — | EDGAR | |
| 2026-06-10 | Joshua S Boger | Director | Grant (A) | +8,150 opt | — | EDGAR | |
| 2026-06-10 | Marwan Sabbagh | Director | Grant (A) | +8,150 opt | — | EDGAR | |
| 2026-06-10 | Frank Zavrl | Director | Grant (A) | +8,150 opt | — | EDGAR | |
| 2026-06-10 | David Quigley | Director | Grant (A) | +8,150 opt | — | EDGAR | |
| 2026-06-10 | Jane H Hollingsworth | Director | Grant (A) | +8,150 opt | — | EDGAR | |
| 2026-02-13 | Kelly Blackburn | EVP, Clinical Development | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-02-13 | Mark De Rosch | EVP, RA and GA and PgM | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-02-13 | Sylvie Gregoire | Director | Grant (A) | +75,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CRVO Insider Holdings
6 insiders · @ $1.56
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Joshua S Boger | Director | 2,012,682 | $3.14M | $3.00M | 6 | 2026-06-15 |
| 2 | John J Alam | CEO & President | 1,496,578 | $2.33M | $282.7K | 11 | 2026-06-10 |
| 3 | Sylvie Gregoire | Director | 1,496,578 | $2.33M | $282.7K | 11 | 2026-06-10 |
| 4 | Matthew Winton | Chief Commercial and Business | 15,000 | $23.4K | $117.1K | 5 | 2026-10-23 |
| 5 | William Robert Elder | CFO, GC & Secretary | 12,500 | $19.5K | $109.3K | 8 | 2026-02-13 |
| 6 | Jane H Hollingsworth | Director | 943 | $1.5K | $0 | 5 | 2026-06-10 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CRVO Board & Officers
As of SEC filings through Oct 23, 2026Directors 8
- Jane H Hollingsworth · since Sep 1, 2020
- Frank Zavrl · since Aug 16, 2023
- Jeffrey V. Poulton · since Aug 16, 2023
- John J Alam · since Aug 16, 2023
- Marwan Sabbagh · since Aug 16, 2023
- Sylvie Gregoire · since Aug 16, 2023
- Joshua S Boger · since Feb 7, 2024
- David Quigley · since Oct 27, 2025
Officers 5
- John J Alam · CEO & President · since Aug 16, 2023
- William Robert Elder · CFO, GC & Secretary · listed since May 2025
- Matthew Winton · Chief Commercial and Business · since Oct 6, 2025
- Mark De Rosch · EVP, RA and GA and PgM · since May 1, 2025
- Kelly Blackburn · EVP, Clinical Development · listed since Feb 2026
10% owners 3
- John J Alam · since Aug 16, 2023
- Joshua S Boger · listed since Feb 2024
- Sylvie Gregoire · since Aug 16, 2023
Changes in the last 10 years (39)
| Feb 13, 2026 | Kelly Blackburn listed as EVP, Clinical Development (previously SVP, Clinical Development) in SEC filings |
| Oct 27, 2025 | David Quigley became a director |
| Oct 6, 2025 | Matthew Winton became Chief Commercial and Business |
| May 14, 2025 | William Robert Elder listed as CFO, GC & Secretary (previously CFO & GC) in SEC filings |
| May 1, 2025 | Mark De Rosch became EVP, RA and GA and PgM |
| Aug 27, 2024 | William Robert Elder listed as CFO & GC (previously GC & Secretary) in SEC filings |
| May 17, 2024 | The company announced the departure of John William Tanner as Chief Financial Officer in an SEC filing |
| Feb 28, 2024 | Joshua S Boger first listed as a 10% owner in an SEC filing |
| Feb 7, 2024 | Joshua S Boger became a director |
| Jan 26, 2024 | Kelly Blackburn listed as SVP, Clinical Development (previously VP, Clinical Development) in SEC filings |
| Oct 25, 2023 | The company announced the departure of Jill Davidson from the board in an SEC filing |
| Sep 15, 2023 | Robert Joseph Cobuzzi Jr. listed as Chief Operating Officer (previously President & CEO) in SEC filings |
| Aug 16, 2023 | Sylvie Gregoire became a director |
| Aug 16, 2023 | Sylvie Gregoire became a 10% owner |
| Aug 16, 2023 | Marwan Sabbagh became a director |
| Aug 16, 2023 | Kelly Blackburn became VP, Clinical Development |
| Aug 16, 2023 | John William Tanner became Chief Financial Officer |
| Aug 16, 2023 | John J Alam became a director |
| Aug 16, 2023 | John J Alam became a 10% owner |
| Aug 16, 2023 | John J Alam became CEO & President |
| Aug 16, 2023 | Jeffrey V. Poulton became a director |
| Aug 16, 2023 | Frank Zavrl became a director |
| Aug 15, 2023 | The company announced the departure of Robert Joseph Cobuzzi Jr. from the board in an SEC filing |
| Aug 15, 2023 | The company announced the departure of Diana M Lanchoney from the board in an SEC filing |
| Jul 26, 2023 | Jill Davidson became a director |
| May 15, 2023 | The company announced the departure of William Karl Hornung as Chief Financial Officer in an SEC filing |
| Feb 16, 2023 | The company announced the departure of Christopher D Galloway as Chief Medical Officer in an SEC filing |
| Nov 13, 2022 | The company announced the departure of Eric Francois from the board in an SEC filing |
| May 18, 2022 | Raven Jaeger became Chief Regulatory Officer |
| Jul 6, 2021 | Eric Francois first on file as a director |
| Jun 25, 2021 | Diana M Lanchoney became a director |
| Oct 19, 2020 | Christopher D Galloway became Chief Medical Officer |
| Sep 23, 2020 | William Robert Elder became GC & Secretary |
| Sep 11, 2020 | Robert Joseph Cobuzzi Jr. first listed as President & CEO in an SEC filing |
| Sep 1, 2020 | Jane H Hollingsworth became a director |
| Jan 7, 2020 | Robert Joseph Cobuzzi Jr. became a director |
| Sep 21, 2018 | William Karl Hornung became Chief Financial Officer |
| Jun 29, 2017 | Robert R Ruffolo became a director |
| Dec 13, 2016 | Ben Shealy listed as Sr VP Finance & Treasurer (previously Senior Vice President Finance) in SEC filings |
Not reported recently (10)
- Robert Joseph Cobuzzi Jr. · Last reported as Chief Operating Officer in an SEC filing dated Feb 14, 2025
- Robert W Adams · Last reported as a director in an SEC filing dated Dec 30, 2022
- Alan G Levin · Last reported as a director in an SEC filing dated Dec 30, 2022
- Mark T Giles · Last reported as a director in an SEC filing dated Dec 30, 2022
- Raven Jaeger · Last reported as Chief Regulatory Officer in an SEC filing dated Aug 26, 2022
- John Gainer · Last reported as a director in an SEC filing dated Jan 30, 2020
- David G Kalergis · Last reported as a director in an SEC filing dated Jan 30, 2020
- Thomas E Byrne · Last reported as General Counsel in an SEC filing dated Jan 9, 2020
- Robert R Ruffolo · Last reported as a director in an SEC filing dated Jun 18, 2018
- Ben Shealy · Last reported as Sr VP Finance & Treasurer in an SEC filing dated Jan 4, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
4 ETFs hold CRVO
4 shown · $989.64K total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $743,017 | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $196,103 | — | 2026-09-30 |
| 3 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.00% | $45,438 | $1.2B | 2026-11-03 |
| 4 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $5,086 | $3.2B | 2026-11-03 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.